We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+37.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$2.62B
AUM Growth
+$630M
Cap. Flow
+$217M
Cap. Flow %
8.29%
Top 10 Hldgs %
54.13%
Holding
172
New
46
Increased
29
Reduced
19
Closed
33

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$64.1M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$36.1M
3
XLRN
Acceleron Pharma
XLRN
+$31.4M
4
PBYI icon
Puma Biotechnology
PBYI
+$17.7M
5
CBAY
Cymabay Therapeutics
CBAY
+$15.9M

Top Sells

Rank Stock Value
1
ARAV
Aravive, Inc. Common Stock
ARAV
+$42.4M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$36.7M
3
RDUS
Radius Health, Inc.
RDUS
+$29.2M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$20.9M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.22%
2 Industrials 0.33%
3 Consumer Staples 0.16%
4 Consumer Discretionary 0.07%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTLA
126
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$425K 0.02%
7,870
– –
ZSAN
127
DELISTED
Zosano Pharma Corporation
ZSAN
$412K 0.02%
714
– –
MOH icon
128
CALL
Molina Healthcare
MOH
$10.4B
$345K 0.01%
+50,000
New +$3.25M
ICPT
129
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$283K 0.01%
+250,000
New +$26.9M
HCM icon
130
HUTCHMED
HCM
$2.13B
$273K 0.01%
+10,000
New +$245K
GRCE
131
Grace Therapeutics
GRCE
$46.3M
$267K 0.01%
3,887
– –
SAGE
132
CALL
DELISTED
Sage Therapeutics
SAGE
$178K 0.01%
215,000
-60,000
-22% -$4.71M
SENS icon
133
Senseonics Holdings Inc
SENS
$503M
$160K 0.01%
+2,500
New +$130K
ALNY icon
134
PUT
Alnylam Pharmaceuticals
ALNY
$32.1B
$45K ﹤0.01%
+420,000
New +$35.8M
INCY icon
135
CALL
Incyte
INCY
$26.3B
$35K ﹤0.01%
+100,000
New +$12.7M
IONS icon
136
CALL
Ionis Pharmaceuticals
IONS
$10.6B
$24K ﹤0.01%
+60,000
New +$3.14M
ANIP icon
137
ANI Pharmaceuticals
ANIP
$1.74B
– –
-125,399
Closed -$5.87M
ARWR icon
138
Arrowhead Research
ARWR
$12.6B
– –
-847,458
Closed -$1.37M
BLUE
139
DELISTED
bluebird bio
BLUE
– –
-1,544
Closed -$2.1M
CDTX
140
DELISTED
Cidara Therapeutics
CDTX
– –
-3,106
Closed -$465K
EW icon
141
Edwards Lifesciences
EW
$52.4B
– –
-18,264
Closed -$719K
EYPT icon
142
EyePoint Inc
EYPT
$431M
– –
-114,956
Closed -$1.97M
ICLR icon
143
Icon
ICLR
$13B
– –
-5,187
Closed -$507K
JAZZ icon
144
Jazz Pharmaceuticals
JAZZ
$16.9B
– –
-85,572
Closed -$13.3M
MOH icon
145
Molina Healthcare
MOH
$10.4B
– –
-8,140
Closed -$530K
OTLK icon
146
Outlook Therapeutics
OTLK
$155M
– –
-5,237
Closed -$837K
RARE icon
147
CALL
Ultragenyx Pharmaceutical
RARE
$2.61B
– –
-100,000
Closed -$6.21M
SRPT icon
148
Sarepta Therapeutics
SRPT
$2B
– –
-1,089,961
Closed -$36.7M
UNH icon
149
UnitedHealth
UNH
$356B
– –
-28,480
Closed -$5.28M
XENE icon
150
Xenon Pharmaceuticals
XENE
$5.85B
– –
-723,853
Closed -$2.28M
3 4 5
6
7

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q3 2017 Portfolio in Review

As of Q3 2017, Perceptive Advisors held 172 positions worth $2.62B, up 32% from $1.99B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Perceptive Advisors deployed $217M of net new capital in Q3 2017, opening 46 new positions and adding to 29 existing holdings. Its largest new stake was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Industrials and Consumer Staples.

On the sell side, the largest reduction was Aravive, Inc. Common Stock, an estimated $42.4M trimmed.

  • Perceptive Advisors's largest Q3 2017 buy was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.
  • Perceptive Advisors added most to Neurocrine Biosciences in Q3 2017, an estimated $64.1M increase.
  • Perceptive Advisors's biggest Q3 2017 reduction was Aravive, Inc. Common Stock, cutting an estimated $42.4M.
  • Perceptive Advisors fully exited Sarepta Therapeutics in Q3 2017, selling an estimated $36.7M.
  • Perceptive Advisors's ten largest holdings make up 54% of its $2.62B portfolio in Q3 2017.
  • Perceptive Advisors opened 46 new positions and closed 33 in Q3 2017.
  • Perceptive Advisors's portfolio value rose 32% quarter-over-quarter to $2.62B.

Based on Perceptive Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.